Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer-Reference-Cited by-同舟云学术

Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer

Published:2015-03 Issue:3 Volume:25 Page:431-439
ISSN:1048-891X
Container-title:International Journal of Gynecological Cancer
language:en
Short-container-title:International Journal of Gynecological Cancer

Author:

Young Melissa Rasar,Higgins Susan A.,Ratner Elena,Yu James B.,Mani Sheida,Silasi Dan-Arin,Azodi Masoud,Rutherford Thomas,Schwartz Peter E.,Damast Shari

Publisher

BMJ

Subject

Obstetrics and Gynaecology,Oncology

Reference31 articles.

1. Carcinoma of the Corpus Uteri

2. Comparative Performance of the 2009 International Federation of Gynecology and Obstetricsʼ Staging System for Uterine Corpus Cancer

3. Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

4. Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy

5. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review;Journal of Personalized Medicine;2023-05-24

2. In reply to Onal et al.;International Journal of Radiation Oncology*Biology*Physics;2021-11

3. Role of brachytherapy in stage III endometrial cancer treated with adjuvant chemotherapy: Identifying factors predictive of a survival benefit;Brachytherapy;2021-07

4. Predictors of Survival in Women with High-Risk Endometrial Cancer and Comparisons of Sandwich versus Concurrent Adjuvant Chemotherapy and Radiotherapy;International Journal of Environmental Research and Public Health;2020-08-16

5. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo;Molecular Oncology;2020-01-14